Skip to content

Study to Evaluate the Optimal Dose of Remifentanil During MRI of the Heart Under General Anaesthesia

Study to Evaluate the Optimal Dose of Remifentanil Required to Ensure Apnoea During Magnetic Resonance Imaging of the Heart Under General Anaesthesia

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02481791
Enrollment
35
Registered
2015-06-25
Start date
2015-07-31
Completion date
2019-12-31
Last updated
2019-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaesthesia, Children, Heart Diseases, Magnetic Resonance Imaging

Brief summary

What is the optimal maintenance dose of remifentanil to ensure apnoea, during breath hold episodes in children having cardiac MR imaging with general anaesthesia?

Detailed description

The management of congenital heart disease depends upon accurate imaging of the heart to define anatomical abnormalities. The use of magnetic resonance imaging has grown in response to this need. Young children, however, are unable to cooperate sufficiently to allow the scan to occur; this necessitates the use of general anaesthesia. The optimal anaesthetic management of children in this situation is complex. Imaging of an acceptable quality depends on a low (normal) heart rate which is relatively constant during the scan and frequent breath holds to avoid respiratory artefacts. Children undergoing such scans commonly have significant cardiac and non-cardiac disease. A technique, currently used at Alder Hey Hospital, is to use intravenous agents to provide anaesthesia: commonly a mixture of the intravenous anaesthetic propofol and the potent opiate remifentanil. The patient's own ventilation is suppressed by the use of remifentanil which also reduces heart rate and heart rate variability. Controlled ventilation is provided via a ventilator and endotracheal tube. Adequate doses of remifentanil are required to ensure suppression of the patient's ventilation whilst excess doses are avoided to reduce the risk of adverse effects (primarily arterial hypotension) and ensure rapid recovery. Remifentanil dose has been studied during surgery(3-6), however this is a unique indication and optimal dosage has not been formally studied. In particular the absence of any stimulation from surgery is likely to mean that substantially lower doses of remifentanil will be required.

Interventions

DRUGRemifentanil and/or propofol

Induction Phase: A dose of remifentanil 1mcg/kg by slow bolus, will be given to facilitate endotracheal intubation. Further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given to ensure an anaesthetised patient.

DRUGpropofol

Equilibrium Period: During this period propofol will be infused at a constant rate of 100mcg/kg/min

Sponsors

Alder Hey Children's NHS Foundation Trust
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Years to 7 Years
Healthy volunteers
No

Inclusion criteria

* Children of one year (of age) or older and younger than 7 years of age. * Scheduled for cardiac MR imaging under general anaesthesia at Alder Hey Children's Hospital. * Parental Consent

Exclusion criteria

* Hypersensitivity to any study drug * Known abnormal response to opiate analgesics or co-morbidity associated with abnormal central control of breathing * Families unable to understand or complete consent * Any other contraindication to proposed anaesthetic technique: at the discretion of the responsible anaesthetist. * Documented significant renal or hepatic dysfunction

Design outcomes

Primary

MeasureTime frameDescription
Diaphragm movement30 secondsThe primary outcome will be movement of the diaphragm during the single test apnoea. The dose of remifentanil will be judged: * A success. If no movement of the diaphragm is detected by MRI imaging during a 30 second test apnoea. * A failure. If movement of the diaphragm is detected during the test apnoea.

Secondary

MeasureTime frameDescription
Scan Quality1 hour• quality of the scan from the respiratory gated sequence (graded by the radiologist who will be blinded to the dose)
Heart Rate1 hour• highest and lowest heart rate (during equilibrium and study period)
Blood pressure1 hour• lowest blood pressure (during equilibrium and study period)
Emergence time1 hour• time to emergence (waking up) at end of scan

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026